Panel vs. Exome vs. Genome: Why More Sequencing Isn't Always More Answers

Zetobit · Bioinformatics Insight Series

Panel vs. Exome vs. Genome: Why More Sequencing Isn't Always More Answers

It's tempting to treat the choice between a targeted panel, an exome, and a whole genome as a ladder — more territory, more diagnoses, strictly better if you can afford it. But breadth trades against depth, interpretability, and turnaround, and the widest test is not always the one that answers your question. Test selection is a design decision, not a default toward "more."

By Kanna Nandakumar, PhD Zetobit LLC

Three sequencing strategies dominate clinical and research genetics. A targeted panel sequences a curated set of genes chosen for a specific phenotype. Whole-exome sequencing (WES) covers the protein-coding regions — roughly 1–2% of the genome, holding the large majority of known pathogenic variants.¹ Whole-genome sequencing (WGS) covers essentially everything, coding and non-coding. Laid out that way, it looks like a simple progression: each step sees more of the genome than the last, so each should find more.

The progression is real for breadth, but breadth is only one axis of a test's usefulness — and optimizing it costs you on the others. What you gain in territory you can lose in depth per base, in the burden of interpreting far more variants, in turnaround time, and in the volume of uncertain and incidental findings you're obligated to handle. The best choice depends on how well you can specify the question in advance, and sometimes the narrower test genuinely outperforms the wider one.

Breadth trades against depth

The most direct tradeoff is between how wide you sequence and how deep. For a fixed sequencing budget, concentrating reads on a small target gives very high depth; spreading them across the exome or genome gives less depth per base.² Panels routinely run at far greater depth than exomes or genomes precisely because the target is small, and that depth translates into real analytical advantages: higher sensitivity for challenging variants, better detection of low-frequency and mosaic variants in hotspot genes, and cleaner calls in difficult regions.²

This is why "more sequencing" can mean "fewer answers" for certain questions. If a patient's phenotype points clearly to a known set of genes — a hotspot for somatic variants, a suspected mosaic condition, a well-defined monogenic disorder — a deep panel may detect variants that a shallower exome would miss entirely. In a study of monogenic obesity and diabetes, a targeted panel achieved significantly higher coverage than exome sequencing and, with its lower cost, faster turnaround, and higher data quality, was judged the more effective first-tier screen for those specific patients.³ More territory did not help; more depth did.

Dimension	Targeted panel	Exome (WES)	Genome (WGS)
Territory	Curated gene set	Coding ~1–2%	Whole genome
Depth per base	Highest	Moderate	Lower, but even
Coverage uniformity	High (in target)	Capture-biased, uneven	Most uniform (PCR-free)
Non-coding / SV / CNV	No	Limited	Best
VUS & incidental burden	Lowest	Higher	Highest raw
Cost & turnaround	Lowest / fastest	Middle	Highest / slowest
Best when	Phenotype well-defined	Broad differential	Broad + non-coding/SV

The counterintuitive part: uniformity can favor the genome

Depth is not the only quality axis, and here the ordering flips. Exome capture relies on hybridization baits that pull down target regions unevenly — low-complexity regions resist good bait design, GC-rich regions capture poorly, and PCR amplification during library prep introduces further bias.⁴ The result is that an exome, despite targeting only coding regions, can leave some clinically important exons poorly covered. Whole-genome sequencing, which is typically PCR-free and capture-free, delivers markedly more uniform coverage of those same exonic regions even at a lower mean depth.⁵

This produces a genuinely surprising outcome: WGS can detect coding variants that WES misses, not because it targets more, but because it covers the shared target more evenly. In one cohort, WGS found diagnostic variants absent from the exome data — including exonic variants in regions the exome had covered poorly — alongside the deep-intronic, structural, and mitochondrial variants only a genome can reach.⁶ "Bigger" and "more uniform" happened to coincide, but it was the uniformity, not the extra territory, that rescued those specific coding calls.

Breadth without a matching question just moves the bottleneck. Sequencing more of the genome doesn't help if the causal variant type is outside every method's reach, or if the analysis can't interpret what's found. Exome and panel both struggle with CNVs, repeats, and low-level mitochondrial heteroplasmy; a genome reaches more of these but demands the pipelines and storage to handle them.⁷ The limiting step is often interpretation, not acquisition — and more raw data can make that step harder, not easier.

Wider tests generate more uncertainty to manage

Every additional gene sequenced is another source of variants of uncertain significance (VUS) and incidental findings. Exome sequencing interprets one to two orders of magnitude more data than a typical panel, with a correspondingly higher chance of VUS and incidental findings; genomes raise the raw volume further still.⁸ For a clinician who must act on — or explain away — every reported uncertain variant, this is a real cost, not a footnote.

But the relationship between breadth and uncertainty is subtler than "wider means more confusion," and this is where test design matters most. A large analysis of over 1.5 million clinical tests found that genomic tests (exome and genome) actually produced a lower rate of inconclusive results due to VUS than multi-gene panels — 22.5% versus 32.6% — and a higher diagnostic yield.⁹ The reason is not biological but procedural: panels typically report all VUS in their targeted genes, while genomic testing uses phenotype correlation to constrain which variants get reported, and for panels the inconclusive rate rose with panel size.⁹ The same study found genome outperformed exome on yield without increasing the inconclusive rate.⁹ Whether breadth helps or hurts depends on the reporting strategy wrapped around it — a design choice, not an inevitability.

Where the extra territory does and doesn't pay off

Two more findings sharpen the decision. First, WGS's advantage over WES is concentrated in variant classes the exome structurally cannot see well: structural variants, copy-number changes, deep-intronic and regulatory variants, and mitochondrial DNA.⁶ If the suspected disease mechanism lives in those classes, the genome is not a luxury; if it doesn't, much of the genome's extra reach is inert for that case. Second, the advantage of broad testing can come from study structure rather than raw breadth: using parent-child trios improves yield and reduces inconclusive rates substantially, and a genome-trio does not necessarily out-diagnose an exome-trio for many indications.⁹ The lever that most improves an answer is frequently not "sequence more of this person" but "sequence the right relatives" or "interpret with better phenotype context."

How to choose: match the test to the question

Test selection is a design problem with several inputs, and depth-of-sequencing is only one:

• Start from the specificity of the phenotype. A well-defined presentation pointing to known genes favors a deep panel — higher sensitivity, lower VUS burden, faster and cheaper; a broad or ambiguous differential favors exome or genome.³
• Match the method to the expected variant class. Coding SNVs/indels are exome territory; suspected CNVs, structural, deep-intronic, regulatory, or mitochondrial mechanisms push toward genome.⁶
• Weigh depth against breadth explicitly for the budget. For hotspot, mosaic, or low-VAF questions, panel depth can beat exome breadth; don't trade the depth you need for territory you don't.²
• Account for uniformity, not just mean depth. WGS's even coverage can outperform a deeper-but-patchy exome for some coding regions; the metric that matters is callable breadth of the relevant genes.⁵
• Design the reporting and family strategy. Phenotype-constrained reporting and trio testing can matter more than test width for both yield and uncertainty; decide these before choosing the assay.⁹

As with the other blind spots in this series, the trustworthy approach makes the decision explicit rather than defaulting: which test, chosen for which variant classes and phenotype, at what depth and uniformity, with what reporting and family design. A reflexive jump to "the biggest test available" looks thorough but can deliver less depth where it's needed, more uncertainty than the case can absorb, and no better answer than a well-chosen narrower assay.

The takeaway

Panel, exome, and genome are not rungs on a ladder from worse to better; they are different instruments for different questions. Breadth buys territory at the price of depth, interpretability, turnaround, and uncertainty — and for a sharply defined phenotype a deep panel can out-diagnose an exome, while for the right coding question a uniform genome can out-detect a patchy exome. "More sequencing" is a means, not a goal. The discipline is to treat test selection as a design decision driven by the question — the phenotype's specificity, the likely variant class, the depth and uniformity required, and the reporting and family strategy — rather than reaching, by reflex, for the largest test on the menu.

References

1. Panels, WES, or WGS for rare disease — exome covers ~2% of the genome but holds ~85% of known pathogenic variants; panels most economical when suspected genes are known. 3billion. 2024. 3billion.io
2. To target or not to target — targeted panels have higher depth of coverage than WES/WGS, more likely to identify low-frequency variants in hotspot genes; less data, lower incidental rate, faster TAT. OGT. ogt.com
3. Targeted panel vs WES for monogenic obesity/diabetes — panel coverage significantly higher than WES; similar yield but lower cost, faster TAT, higher data quality → effective first-tier test. Front Genet / PMC. 2024. PMC10847719
4. WGS coverage uniformity superior to WES — low-complexity regions resist bait design (off-target capture); WES requires PCR (GC bias); WGS PCR-free reduces bias. Front Line Genomics. 2022. frontlinegenomics.com
5. WGS as first-tier — at typical depth WGS offers improved uniformity of exonic coverage vs WES; median exonic coverage 40×, genome-wide 10×/20× at 98%/93%. Genet Med. 2018. gimjournal.org
6. Lionel et al. — WGS detected diagnostic variants missed by WES in ~26% of cases: deep-intronic SNVs, small CNVs, ncRNA, mitochondrial, and exonic SNVs in regions poorly covered by WES. Genet Med. 2018. PMID 28771251
7. WES/panels limited for low-level heteroplasmic mtDNA, CNVs, and repeats — potentially within reach of WGS but requiring adapted pipelines/storage; interpretation burden scales with breadth. Eur J Hum Genet / PMC. 2018. PMC5945679
8. WES interprets 1–2 orders of magnitude more data than panels with higher chance of VUS and incidental findings, and less depth (less sensitive to mosaicism); WGS highest cost/storage/VUS. NHS Genomics Education. genomicseducation.hee.nhs.uk
9. Over 1.5M tests — genomic tests lower VUS-inconclusive rate (22.5% vs 32.6%) and higher yield (17.5% vs 10.3%) than panels; panel inconclusive rate rose with size; genome > exome yield without more inconclusives; trios improved yield. medRxiv. 2022. medrxiv.org

Zetobit LLC · Bioinformatics Insight Series · Lexington, KY · zetobit.com